Cargando…

The impact of inhibitors on the quality of life in patients with hemophilia

OBJECTIVE: To investigate the association of health-related quality of life in hemophilia patients with inhibitor and clinical and demographic characteristics. METHODS: In this multi-center cross-sectional study, 41 male patients with hemophilia A were investigated from May to October 2021. All pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Haghpanah, Sezaneh, Naderi, Majid, Kamalian, Sepideh, Tavoosi, Hakimeh, Parand, Shirin, Javanmardi, Neda, Karimi, Mehran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338721/
https://www.ncbi.nlm.nih.gov/pubmed/37456083
http://dx.doi.org/10.1177/20503121231182284
_version_ 1785071687140638720
author Haghpanah, Sezaneh
Naderi, Majid
Kamalian, Sepideh
Tavoosi, Hakimeh
Parand, Shirin
Javanmardi, Neda
Karimi, Mehran
author_facet Haghpanah, Sezaneh
Naderi, Majid
Kamalian, Sepideh
Tavoosi, Hakimeh
Parand, Shirin
Javanmardi, Neda
Karimi, Mehran
author_sort Haghpanah, Sezaneh
collection PubMed
description OBJECTIVE: To investigate the association of health-related quality of life in hemophilia patients with inhibitor and clinical and demographic characteristics. METHODS: In this multi-center cross-sectional study, 41 male patients with hemophilia A were investigated from May to October 2021. All patients were registered at the Hemophilia Clinic affiliated with Shiraz and Zahedan Universities of Medical Sciences in Iran. Health-related quality of life of the patients was evaluated by the Short Form-36 questionnaire. RESULTS: The patients’ mean ± SD of age was 36.9 ± 13.2 (range: 18–76) years. Eleven patients (26.8%) were inhibitor positive. In univariate analysis, physical function, mental health dimension, and total Short Form-36 scores were significantly lower in the inhibitor-positive patients (p < 0.001, p = 0.045, and p = 0.035, respectively). Moreover, patients with severe disease showed significantly lower scores in physical function (p < 0.001), physical health dimension (p = 0.018), and total Short Form-36 (p = 0.031) than those with mild and moderate hemophilia. Also, blood-borne infections showed a significant association with lower score in physical health dimension (p = 0.038). In addition, annual bleeding rate showed significant negative correlations with physical health dimension (r(s) = −0.609, p < 0.001), mental health dimension (r = −0.317, p = 0.044), and total Short Form-36 (r = −0.455, p = 0.003) scores. In multiple linear regression analysis, disease severity revealed a significant negative relationship with scores in physical function (p = 0.001), role physical (RP) (p = 0.015), general health (GH) (p = 0.006), physical health dimension (p = 0.006), and marginally in total Short Form-36 score (p = 0.054). Also, age of the patients showed a significant negative association with physical function and GH scores (p < 0.001 and p = 0.015, respectively). CONCLUSION: Disease severity and age were shown as independent factors affecting health-related quality of life, but inhibitor alone was not an independent influencing factor. Reduced health-related quality of life was also observed in hemophilia patients with higher annual bleeding rate and blood-borne infections. Therefore, it is necessary to pay more attention to these subgroups. Further studies with larger sample size are needed for more accurate results.
format Online
Article
Text
id pubmed-10338721
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-103387212023-07-14 The impact of inhibitors on the quality of life in patients with hemophilia Haghpanah, Sezaneh Naderi, Majid Kamalian, Sepideh Tavoosi, Hakimeh Parand, Shirin Javanmardi, Neda Karimi, Mehran SAGE Open Med Original Article OBJECTIVE: To investigate the association of health-related quality of life in hemophilia patients with inhibitor and clinical and demographic characteristics. METHODS: In this multi-center cross-sectional study, 41 male patients with hemophilia A were investigated from May to October 2021. All patients were registered at the Hemophilia Clinic affiliated with Shiraz and Zahedan Universities of Medical Sciences in Iran. Health-related quality of life of the patients was evaluated by the Short Form-36 questionnaire. RESULTS: The patients’ mean ± SD of age was 36.9 ± 13.2 (range: 18–76) years. Eleven patients (26.8%) were inhibitor positive. In univariate analysis, physical function, mental health dimension, and total Short Form-36 scores were significantly lower in the inhibitor-positive patients (p < 0.001, p = 0.045, and p = 0.035, respectively). Moreover, patients with severe disease showed significantly lower scores in physical function (p < 0.001), physical health dimension (p = 0.018), and total Short Form-36 (p = 0.031) than those with mild and moderate hemophilia. Also, blood-borne infections showed a significant association with lower score in physical health dimension (p = 0.038). In addition, annual bleeding rate showed significant negative correlations with physical health dimension (r(s) = −0.609, p < 0.001), mental health dimension (r = −0.317, p = 0.044), and total Short Form-36 (r = −0.455, p = 0.003) scores. In multiple linear regression analysis, disease severity revealed a significant negative relationship with scores in physical function (p = 0.001), role physical (RP) (p = 0.015), general health (GH) (p = 0.006), physical health dimension (p = 0.006), and marginally in total Short Form-36 score (p = 0.054). Also, age of the patients showed a significant negative association with physical function and GH scores (p < 0.001 and p = 0.015, respectively). CONCLUSION: Disease severity and age were shown as independent factors affecting health-related quality of life, but inhibitor alone was not an independent influencing factor. Reduced health-related quality of life was also observed in hemophilia patients with higher annual bleeding rate and blood-borne infections. Therefore, it is necessary to pay more attention to these subgroups. Further studies with larger sample size are needed for more accurate results. SAGE Publications 2023-07-10 /pmc/articles/PMC10338721/ /pubmed/37456083 http://dx.doi.org/10.1177/20503121231182284 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Haghpanah, Sezaneh
Naderi, Majid
Kamalian, Sepideh
Tavoosi, Hakimeh
Parand, Shirin
Javanmardi, Neda
Karimi, Mehran
The impact of inhibitors on the quality of life in patients with hemophilia
title The impact of inhibitors on the quality of life in patients with hemophilia
title_full The impact of inhibitors on the quality of life in patients with hemophilia
title_fullStr The impact of inhibitors on the quality of life in patients with hemophilia
title_full_unstemmed The impact of inhibitors on the quality of life in patients with hemophilia
title_short The impact of inhibitors on the quality of life in patients with hemophilia
title_sort impact of inhibitors on the quality of life in patients with hemophilia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338721/
https://www.ncbi.nlm.nih.gov/pubmed/37456083
http://dx.doi.org/10.1177/20503121231182284
work_keys_str_mv AT haghpanahsezaneh theimpactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT naderimajid theimpactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT kamaliansepideh theimpactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT tavoosihakimeh theimpactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT parandshirin theimpactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT javanmardineda theimpactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT karimimehran theimpactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT haghpanahsezaneh impactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT naderimajid impactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT kamaliansepideh impactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT tavoosihakimeh impactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT parandshirin impactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT javanmardineda impactofinhibitorsonthequalityoflifeinpatientswithhemophilia
AT karimimehran impactofinhibitorsonthequalityoflifeinpatientswithhemophilia